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a b s t r a c t 
Cell-based immunotherapies have been selected for the front-line cancer treatment approaches. Among them, 
CAR-T cells have shown extraordinary effects in hematologic diseases including chemotherapy-resistant acute 
lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL). In this 
approach, autologous T cells isolated from the patient’s body genetically engineered to express a tumor specific 
synthetic receptor against a tumor antigen, then these cells expanded ex vivo and re-infusion back to the patient 
body. Recently, significant clinical response and high rates of complete remission of CAR T cell therapy in B- 
cell malignancies led to the approval of Kymriah and Yescarta (CD19-directed CAR-T cells) were by FDA for 
treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Despite promising therapeutic 
outcomes, CAR T cells also can elicit the immune-pathologic effects, such as Cytokine Release Syndrome (CRS), 
Tumor Lysis Syndrome (TLS), and on-target off-tumor toxicity, that hampered its application. Ineffective control 
of these highly potent synthetic cells causes discussed potentially life-threatening toxicities, so researchers have 
developed several mechanisms to remote control CAR T cells. In this paper, we briefly review the introduced 






































Cancer is defined as abnormal activity of different cell cycles protein,
hich results in cells’ uncontrolled proliferartion [1] . Cell-based im-
unotherapies have been selected for the front-line cancer treatment ap-
roaches [2] . Recently, different strategies such as monoclonal antibod-
es (mAbs), tumor vaccines, immune checkpoint blockades, cytokine-
nduced killers (CIKs), bispecific antibodies, tumor-infiltrating lympho-
ytes (TIL), and chimeric antigen receptor T (CAR-T)have been recruited
o overcome cancer [3] . Monoclonal antibodies such as Herceptin and
etuximab showed desirable effects on patients with malignant tumors.
urrently, Food and Drug Administration (FDA) has approved some
mmune checkpoint blocking agents, including Ipilimumab (anti-CTLA-
mAb), Pembrolizumab, and Nivolumab (anti-PD-1mAb)for melanoma
atients [4] . Cell-based immunotherapy relies on using intact and liv-
ng immune cells that are extracted from the human body and grown∗ Corresponding author at: Breast Disease Research Center, Tehran University of M
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 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) o increase their amount and power or genetically-modified to boost
heir ability to find and kill tumor cells. T cells play a key role (moni-
oring and killing potentially malignant cells) in the cell-mediated im-
une response. Various types of therapies have been developed to cul-
ure, redirect, and/or enhance T cells against tumors. T cell-based
doptive immunotherapy is one of them, which includes three models:
umor-infiltrating lymphocytes, T cell receptor(TCR)-modified T cells,
nd chimeric antigen receptor T cells (CAR-T cells). Compared with
AR-T cells, the efficacy of TILs and TCR-modified T cells is not substan-
ial, because they don’t modify T cells extremely. Besides, their process
f generation, little success rate, and dependency on vaccination have
een limited the development of these approaches [5] . 
CARs were described in 1987 by Diamond et al. [6] and shown
o have extraordinary effects in hematologic diseases including
hemotherapy-resistant acute lymphoblastic leukemia (ALL) [7–11] ,
hronic lymphocytic leukemia (CLL) [12 , 13] , and non-Hodgkin lym-edical Sciences, Tehran, Iran. 
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1  homa (NHL) [14 , 15] . However, these modified T cells for cancer im-
unotherapy of solid tumors have not yielded successful results yet.
ARs mostly consist of a single-chain variable fragment of an antibody
ScFv) recognizing tumor antigen, a transmembrane domain, intracellu-
ar single-chain tyrosine-based activation motifs (ITAMs) from CD3 zeta
hain (CD3 𝜁), and a co-stimulatory domain [16] . The activation process
f these engineered T cells is totally independent of the major histo-
ompatibility complex (MHC) [17] . Researchers have developed differ-
nt generations of them composing of (i) CD3 𝜁 or Fc receptor 𝛾 (FcR 𝛾)
ctivating signal in an intracellular motif which results in transient T
ell activation [18] (ii) one activating co-stimulatory domain (CD28 or
-1BB or OX-40) (iii) two or more activating co-stimulatory domains
19 , 20] (iv) T cells redirected for universal cytokine killing (TRUCKS)
hat are engineered to produce IL-12 for tumor environment remodel-
ng [21 , 22] . Within weeks of engineered T cell administration, cytokine
roduction, targeted cells death, and stimulation of T cell proliferation
re predicted [23 –25] . Some limitations, including poor permeability,
ifficulties of target selection, and suppressive tumor microenvironment
vershadowed the CAR-T cells’ clinical outcome [21] . 
Although CAR-T cells made some progress in the treatment of the
ematologic malignancies, some adverse effects, including fatal com-
lications, have been reported in some patients who have received
AR-modified T cells. This review article highlights the different CARs-
elated toxicities and introduces potential strategies to overcome them.
. Adverse effects of CAR-T cells 
CAR-T cell infusion is not entirely safe; therefore, patients mostly
xperience some adverse reactions, including on-target on-tumor toxic-
ty, on-target off-tumor toxicity, and other adverse reactions which are
isted below. 
.1. On-target on-tumor toxicity 
.1.1. Cytokine Release Syndrome (CRS) 
CAR-T cell therapy not only kills tumor cells but also results in the
roduction of a considerable level of cytokines, including tumor necrosis
actor-alpha (TNF- 𝛼), interferon 𝛾 (IFN- 𝛾), IL-6, and IL-10 [24 , 26] . This
ytokine production is called cytokine release syndrome (CRS) and leads
o some clinical side effects such as fever, tachycardia, hypotension, and
ypoxia, which may finally result in rapid death. CAR-T cell dosage and
isease burden are considered as biomarkers that can predict CRS during
AR-T cell therapy [26–28] . 
.1.2. Tumor Lysis Syndrome (TLS) 
Destruction, of a large number of tumor cells, causes a rapid re-
ease of intracellular substances and brings about some metabolic disor-
ers, including hyperuricemia, hyperphosphatemia, hypocalcemia, and
etabolic acidosis, which result in acute renal failure and death [25] . 
.2. On-target off-tumor toxicity 
On-target off-tumor toxicity is an unavoidable side effect caused by
he shared expression of the target antigen on normal tissues. For in-
tance, some target antigens, including CD19, CD20, and CD22, are ex-
ressed on some normal blood cells that create an obstacle in the appli-
ation of CAR-T cells in hematologic tumors [11] . 
.3. Other adverse effects 
The risk of GVHD (graft versus host disease) incidence may be in-
reased by donor-derived CAR-T cells. Maus et al. showed that combined
CR and CAR cells could decrease GVHD risk. Since murine antibodies
re the source of the most recognizing domain of CARs, host anti-CAR
esponses may be present in some patients [29 , 30] . Maus et al. reported
hat the application of CAR-T cells derived from murine mAb against2 uman mesothelin led to acute anaphylaxis. Moreover, a higher level
f IgE is a consequence of repeated CAR-T cell infusion [29] . Although
here was no evidence of viral vector-induced immortalization of the
ells, viral vector-transfected T cells may increase the risk of oncogene-
is [31] . Furthermore, neurotoxicity is the other adverse effect of CAR-
 cell therapy, which usually includes confusion, delirium, expressive
phasia, obtundation, myoclonus, and seizure [7] . 
. Strategies for remote controlling of CAR-T cells 
Although CAR-T cell therapy is a promising therapeutic approach,
he immune-pathologic effects of this treatment, such as CRS and on-
arget off-tumor toxicity, have hampered its application [32 , 33] . CAR-T
ells are engrafted and persist indefinitely in a patient’s body, so con-
rolling its unpredicted toxicities is vital. Recent advances in synthetic
iology provide new methods to control the immune response in or-
er to augment the accuracy of synthetic immune cell therapies by re-
ote and noninvasive control. Sensing, processing, and responding to
he dynamic environments by living cells fulfilled using various biolog-
cal mechanisms. Specifically, by rewiring cellular ligands, receptors,
nd signaling pathways into bio-circuitry they can sense and respond
o multiple inputs, for example, remote stimuli. Accordingly, synthetic
mmune cells, which genetically engineered with remote-controlled cir-
uits, supply non-invasive and site-specific activation that capable of
djusting the potency, specificity, and safety of immune responses. Re-
ote control of immunity can apply external targeting with signals such
s light or heat, or autonomous circuits. For further information look-
ng at the Gamboa et al. review about the remote control mechanisms
n synthetic immunity [34] . Several approaches have been developed to
iminish these adverse effects that elaborate in three classes, including
uicide switches, endogenous switches, and exogenous switches ( Fig.1 )
hat are described in the following paragraphs briefly. 
Also, Table 1 summarizes the strengths and weaknesses of these ap-
roaches, and ongoing clinical trials using these methods are shown in
able 2 . 
.1. Suicide switches 
Suicide genes are genetically encoded elements integrated into CAR-
 cells that allow the elimination of the introduced T cells in case of un-
xpected toxicities. They are activated by the administration of a phar-
aceutical agent [53 , 54] . These genes include inducible caspase 9 (iC9),
runcated EGFR (tEGFR or EGFRt), herpes simplex virus thymidine ki-
ase (HSV-TK), and CD20 [36] . 
.1.1. iCasp9 
iCasp9 (inducible caspase 9) is a pro-apoptotic safety switch made by
he fusion of a mutant FKBP12, a receptor for the immunosuppressant
rug FK506, to a modified human caspase 9 using a flexible Ser-Gly-Gly-
ly-Ser-linker [55] . The mutant FKBP12 moiety allows a small molec-
lar chemical inducer of dimerization (CID) (AP1903/AP20187) to at-
ach to it while it cannot bind to the wild-type FKBP12. The modified
aspase 9 is a truncated protein without the physiological dimerization
omain or caspase recruitment domain (CARD) to minimize basal signal-
ng. Conditional intravenous administration of a CID (such as AP1903)
roduces crosslinking of the drug-binding domains of this chimeric pro-
ein that results in the dimerization of caspase 9, and whereby activates
he downstream executioner caspase3 molecules, leading to apoptosis of
he cells expressing the fusion protein [33] . In-vitro and in-vivo experi-
ents show that this safety switch can cause apoptosis of approximately
9% of donor T cells using a 10 nM dose of AP1903 [56] . 
.1.2. HSV-TK 
The Thymidine kinase (TK) derived from Herpes simplex viruses-
 (HSV-1) (HSV-TK), which has been probably evolved distinctly from
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Fig. 1. Safety strategies to overcome CAR-T-cell-related toxicity. A Conditional intravenous administration of AP1903 beginnings dimerization of caspase9 that 
activates the downstream executioner caspase3 molecules, resulting in cellular apoptosis of cells expressing the CAR-T cells. B, After the conditional intravenous 
administration of GCV, HSV-TK catalyzes the phosphorylation of GCV that produces a toxic GCV-triphosphate that causes competitive inhibition of guanosine 
incorporation with subsequent inhibition of DNA synthesis and death. C, A synNotch receptor recognizes a tumor antigen, then undergoes cleavage, causing the 
release of the intracellular transcriptional domain that enters into the nucleus and activates expression of a CAR-T cell that targeting another tumor antigen. D, Upon 
administration of a heterodimerizing small molecule and recognition of the antigen, the co-stimulatory domains and the splitting downstream ITAMs joined together 
that cause activation of CAR-T cell. E, The first moiety provides a CD3 𝜁 -mediated activation signal after recognition of the first antigen, and the co-stimulatory signal 
is prepared by secondary moiety after recognition of the second antigen so that CAR-T cells can become completely activated just after dual-antigen recognition. F, 
The iCAR includes a receptor that is specific to the antigens expressed exclusively on normal tissue (PSMA), and an inhibitory intracellular signaling domain (PD-1 
or CTLA-4) to restrict T cell activity so that in the presence of both PSMA and tumor-associate antigen (in healthy cells), iCAR suppresses itself. G, Tandem CARs 
consist of two tandemly linked scFvs targeting different tumor antigens that are combined with one activation domain. H, administration of bispecific T-cell engager 
redirects and regulates CAR activity to target antigen-positive tumor tissues. I, CAR-T cells expressing CD20 or EGFRt antigen deleted with an approved monoclonal 
antibody, such as rituximab or cetuximab through CDC/ADCC. 
3 
E. Moghanloo, H. Mollanoori, M. Talebi et al. Translational Oncology 14 (2021) 101070 
Table 1 
The strengths and weaknesses of various safety strategies of CAR-T cells. 
÷Molecular switches Pros Cones Efficiency Reference 
Suicide 
switches 
HSV-TK 1. Remarkable function 
and safety 
2. The best studied 
technique 
1. Time-consuming process 
2. Premature end of the treatment 
3. Immunogenicity 
4. Clinical incompatibility of GCV 
5. Irreversible depletion 
6. Cell-cycle dependency 
More than 90% 
[32 , 35 –37] 
[35 , 36 , 38 , 39] 
[38–40] 
[38–42] 
iCasp9 1. Human-derived, no 
immunogenicity 
2. Highly effective and acts 
rapidly 
3. Clinical compatibility 
and optimal 
bio-distribution 
4. Use non-therapeutic 
agent 
5. Long-term outcome 
1. Irreversible depletion 
2. Premature end of 
the treatment 
> 90% elimination 
of T cells within 
30 min of CID 
administration 
CD20 1. Human-derived, no 
immunogenicity 
2. Acts rapidly 
1. Limited bio-distribution and tissue 
penetration of antibody 
2. Irreversible depletion 
3. Premature end of 
the treatment 
4. Limited capacity of CDC/ADCC in 
the patients treated with 
chemotherapy 
5. On-target toxicity from mAb 
6. Pro-drug infusion reaction 
86–97% 
EGFRt 1. Human-derived, no 
immunogenicity 
2. Acts rapidly 
3. The possibility of 
in-vivo tracking 
1. Limited bio-distribution and tissue 
penetration of antibody 
2. Irreversible depletion 
3. Premature end of 
the treatment 
4. Limited capacity of CDC/ADCC in 
the patients treated with 
chemotherapy 
5. On-target toxicity from mAb 




synNotch 1. Highly controlled 
custom behaviors of CAR-T 
cells 
2. Localized activity 
1. Inability to control the intensity of 
the CAR T-cell activity 
2. Inability to control CAR-T cells in a 
temporal manner 
3. Difficulties in choosing 2 effective 
antigens 
[39 , 43 –45] 
[39 , 46] 
[32 , 39 , 47] 
iCAR 1. Discrimination between 
malignant and healthy 
cells 
2. Regulation of CAR-T 
cells responses in an 
antigen-selective manner 
1. Inability to control the intensity of 
the CAR T-cell activity 
2. Inability to control CAR T-cells in a 
temporal manner 





1. Preventing tumor 
antigen loss and tumor 
escape 
2. Increase precise 
destruction of tumor cells 
1. Inability to control the intensity of 
the CAR T-cell activity 
2. Inability to control CAR T-cells in a 
temporal manner 
3. Potential on-target off-tumor 
toxicity 






1. Controllable CAR-T cells 
activity 
2. Ability to target 
different antigens 
1. Immunogenicity 
2. The limited number of 
FDA-approved anti-tumor Abs 
3. Need more attention to choose 
small molecules 
[48–50] 
[39 , 51 , 52] 
On-switch CAR 1. Controllable CAR-T cells 
activity 
2. Multiple specific 
cytotoxicity cycles using a 
small molecule 
3. Modular design 
1. Need more attention to choose 
small molecules 
2. Neither prevent on-target off-tumor 
toxicity nor letting spatial control 
4 
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Table 2 
The clinical trials of the next generation of CAR-T cells in cancer immunotherapy. 
Safety strategy Target Phase Stage Default state (On or Off) Identifier 
HSV-TK CD44v6 Phase1/2 Recruiting ON NCT04097301 
EGFRt CD19 Phase1/2 Recruitingntv ON NCT02028455 
CD19 Phase1Recruiting ON NCT02146924 
CD19 Phase1 Active, not recruiting ON NCT01815749 
CD19 Phase1 Not yet recruiting ON NCT03579888 
CD19 Phase1 Active, not recruiting ON NCT02051257 
CD19 Phase1/2 Active, not recruiting ON NCT01865617 
CD19 Phase1 Recruiting ON NCT03103971 
CD19 Phase1 Recruiting ON NCT03085173 
CD19 Phase1 Recruiting ON NCT02706405 
CD19 Phase1 Active, not recruiting ON NCT01683279 
CD19 Phase1 Recruiting ON NCT03389230 
CD123 Phase1 Recruiting ON NCT02159495 
CD123 Phase1 Recruiting ON NCT03114670 
CD123 Phase1/2 Recruiting ON NCT04109482 
CD22 Phase1 Active, not recruiting ON NCT03244306 
CD22 Phase1 Active, not recruiting ON NCT03330691 
CD171 Phase1 Recruiting ON NCT02311621 
EGFR Phase1 Recruiting ON NCT03618381 
EGFR Phase1 Recruiting ON NCT03638167 
HER2 Phase1 Recruiting ON NCT03500991 
BCMA Phase1 Active, not recruiting ON NCT03070327 
B7H3 Phase1 Recruiting ON NCT04185038 
MUC16 Phase1 Recruiting ON NCT02498912 
CS1 Phase1 Recruiting ON NCT03710421 
ICasp9 GD2 Phase1 Active, not recruiting ON NCT01822652 
GD2 Phase1 Active, not recruiting ON NCT01953900 
GD2 Phase1 Completed ON NCT02107963 
GD2 Phase1 Recruiting ON NCT03721068 
GD2 Phase2 Recruiting ON NCT02765243 
GD2 Phase1/2 Recruiting ON NCT02992210 
GD2 Phase1/2 Recruiting ON NCT03373097 
GD2 Phase1 Not yet recruiting ON NCT04196413 
CD19 Phase1/2 Recruiting ON NCT03016377 
CD19 Phase1 Recruiting ON NCT03696784 
CD19 Phase1/2 Recruiting ON NCT03050190 
CD19 Phase1/2 Recruiting ON NCT03373071 
Mesothelin Phase1/2 Recruiting ON NCT02414269 
CD19/CD20Phase1/2 Recruiting ON NCT03125577 
/CD22/CD30/CD38 
/CD70/CD123 
GPC3 Phase1 Not yet recruiting ON NCT04377932 
TanCAR CD19/20 Phase1 Active, not recruiting ON NCT03019055 
CD19/20 Phase1/2 Recruiting ON NCT03097770 
CD19/20 Phase1/2 Recruiting ON NCT04186520 
CD19/22 Phase1/2 Active, not recruiting ON NCT03185494 
iCAR CD19 Early Phase 1 Not yet recruiting OFFtv NCT03824951 





































fi  K1, the cell-cycle dependent cytosolic TK, can phosphorylate thymi-
ine, various other pyrimidines, and also pyrimidine and purine analogs.
ri-phosphorylated nucleoside analogs are cytotoxic because they in-
erfere with DNA synthesis. Several pro-drugs for the HSV-TK system
ave been evaluated, including ganciclovir (GCV), acyclovir (ACV), and
rivudin (BVDU) and among them, GCV was found to be the most ef-
ective pro-drug for this system [57] . By conditional administration of
CV, HSV-TK catalyzes the phosphorylation of GCV that produces a
oxic GCV-triphosphate resulting in competitive inhibition of guanosine
ncorporation with subsequent inhibition of DNA synthesis and cellular
eath [53] . 
.1.3. CD20 and EGFRt safety switches 
The other suicide gene-based technology is the co-expression of the
AR-T cell, and a targetable component, a well-known surface anti-
en such as CD20 or the truncated epidermal growth factor recep-
or (EGFRt). This approach allows a selective cell removal through
he complement-dependent cytotoxicity (CDC) and antibody-dependent
ell-mediated cytotoxicity (ADCC) after administration of a specific
onoclonal antibody. Rituximab has been used as a clinically approved5 onoclonal antibody for CD20 and cetuximab for EGFRt [40 , 53 , 58 , 59] .
sing these antibodies has some disadvantages such as limited bio-
istribution and tissue penetration and limited CDC/ADCC capacity in
he patient that already have been treated by chemotherapy. This issue
as been addressed by creating anti-idiotype CARs recognizing CD19-
pecific CARs or synthesizing a short peptide epitope (E-tag) in the ex-
racellular domain of the CAR and using an anti-E-tag CAR in order to
mit the anti-tumor CARs [60 , 61] . 
.2. Endogenous switches 
.2.1. Combinatorial target-antigen recognition 
Because of the few available tumor-specific antigens (TSAs), CAR-
 cells always target tumor-associated antigens (TAAs) that are weakly
xpressed in normal tissues or bystander cells. So, even in successful
reatment, probably normal cells are targeted and eradicated. This effect
s called on-target off-tumor toxicity, an unavoidable side effect [43] .
dding a second antigen specificity could potentially prevent this toxi-
ity. There are two strategies to combine different target antigens. The
rst one is constructing two intact CARs into one vector or tandem con-




























































































































t  truction of two scFv domains in one CAR molecule (tandem CAR or
anCAR) that are fully activated when each antigen is engaged [62 , 63] .
eparation of the customary CAR-T cell into two complementary moi-
ties is another approach to raise safety and control T-cell response.
he intracellular activating regions of a complete CAR-T cell (CD3 𝜁)
nd co-stimulatory activation domains (CD28 and/or 4-1BB) are trans-
uced separately within two half-baked CAR-T cells. The first moiety
rovides a CD3 𝜁 -mediated activation signal after recognition of antigen
, and the co-stimulatory signal is prepared by the second moiety when
ntigen 2 is involved. In this approach, engineered T cells can become
ompletely activated just when they encounter with 1 positive /2 positive tar-
et cells, so the dual-antigen binding is necessary for complete CAR-T
ell activation [64–66] . In other words, each moiety provides a discrete
ignal that alone is inadequate to mediate T-cell activation. However, a
ombination of these signals synergizes and stimulates a complete T-cell
esponse. 
.2.2. Synthetic Notch receptors (synNotch) 
Among three parts of a wild-type Notch receptor, synNotch just re-
ains the core regulatory domain of the cell-cell signaling receptor Notch
hat cleaves the receptor and releases a transcriptional activator domain.
owever, the extracellular ligand-binding domain replaced by a syn-
hetic single-chain variable fragment (scFv) and the intracellular tran-
criptional domain replaced by synthetic intracellular transcriptional
omains activates a downstream desired target gene [67] . In this ap-
roach, the synNotch receptor first recognizes a tumor antigen then un-
ergoes induced trans-membrane cleavage like as the wild-type Notch
ctivation and thereby releasing the intracellular transcriptional domain
o enter the nucleus and activates expression of a CAR-T cell that tar-
eted another tumor antigen [43 , 44] . 
.2.3. Inhibitory CAR (iCAR) 
In human T cells, PD-1 and CTLA-4 intracellular signaling domains
re able to reduce TCR signaling, thereby declined T-cell cytokine pro-
uction and its lysis activity. Through smart use of this ability, Fedorov
t al. designed a self-regulating safety switch that allows for discrim-
nation between the tumor and healthy cells. Theoretically, the iCAR
ncludes a receptor that is specific to the antigens expressed exclusively
n normal tissue (PSMA), and an inhibitory intracellular signaling do-
ain (PD-1 or CTLA-4) to restrict T cell activity. In the presence of both
SMA and CD-19 (healthy cells), the iCAR is inhibited by the activity
f the intracellular signaling domains (PD-1), but in tumor cells, the ab-
ence of PSMA prevents iCAR-mediated inhibition of the CAR, thereby
-cell activation and target cell lysis [46] . 
.3. Exogenous switches 
.3.1. Bispecific T cell engager 
Bispecific T-cell engagers are defined as antibodies or derived pro-
eins with multiple binding sites, each with a unique antigen specificity
hat allows them to bridge two or more cells by a physical link. One
inding site links to an antigen on one given cell, and the other binding
ite links to an antigen on a different cell [68] . Recently, the folate-FITC
onjugate was used as a bispecific small molecule switch in the introduc-
ion of more secure CAR-T cells. In this approach, a synthetic CAR was
onstructed that binds to a fluorescein isothiocyanate (FITC) molecule
alled "universal" anti-FITC–directed CAR-T cell. The constructed cell
oes not immediately bind to the antigen on the tumor cells, but it is
onverted to the effector cell by binding to the small bispecific molecule
folate-FITC conjugate). The CAR is inactive and cannot target normal
ells in the lack of folate-FITC conjugate. After the administration of the
onjugate, this bispecific T-cell engager redirects and regulates CAR ac-
ivity to target folate receptor-positive tumor tissues. The alpha isoform
f folate receptor (FR) is expressed in the nearly 50% of cancers such as
reast, lung, uterus, and ovarian, but it is expressed in very low levels in
he normal tissues [49] . So far, several anti-tumor antibodies, including6 nti-EGFR, anti-Her2, anti-CD20, anti-CD19, and anti-CD22 antibodies
ere conjugated to FITC to create different bispecific small molecule Ab-
ITC which redirected anti-FITC –CAR-T cells binding to the tumor cells
48 , 50] . Briefly, in this manner CAR activation and proliferation were
igorously relying on the existence of both bispecific T-cell engager and
ntigen-positive cells, and also, it was dose titratable with a bispecific
mall molecule switch that makes it more controllable. 
.3.2. On-switch CAR 
The design of on-switch CAR-T cells inspired by the normal T cell
ctivation process in which activation of T cell receptors (TCRs) and a
o-stimulatory receptor on the separately expressed polypeptides initi-
tes an immune response [69] . However, in conventional CARs, the anti-
en recognition domain (scFv), the main signaling motif (such as ITAMs
rom TCR subunit CD3z), and co-stimulatory motifs are artificially co-
ocalized [70] . So, to imitate normal T cell response, the key signaling
odules are distributed into physically separate polypeptides that can
e conditionally reassembled when a heterodimerizing small-molecule
gent is added. The on-switch CARs consist of two split parts includ-
ng an extracellular scFv with co-stimulatory domains and a key down-
tream signaling element (the immunoreceptor tyrosine-based activa-
ion motifs (ITAMs) from the T cell receptor CD3z subunit) that each of
hem contains heterodimerization domains that interact with each other
pon binding of a heterodimerizing small molecule. The therapeutic ac-
ivity of the on-switch CAR-T cell requires a small priming molecule in
ddition to the cognate antigen, and neither small molecule nor antigen
hould activate it alone. This CAR provides a small molecule–dependent,
itratable, and reversible control over the CAR T cell activity, thereby
lleviating toxicity [36 , 51 , 52] . 
. Concluding remarks 
Targeting malignant cells using engineered CAR-T cells is a great
dvance in the treatment of cancer. This approach is an effective new
reatment for hematologic malignancies. So far, two CAR-T cell prod-
cts, including Tisagenlecleucel and Axicabtagene Ciloleucel have been
pproved by the USA FDA for the clinical use in case of pediatric acute
ymphoblastic leukemia (ALL), adult diffuse large B-cell lymphoma sub-
ypes (DLBCL), and axicabtagene ciloleucel for DLBCL (71). Despite the
ignificant progress achieved in the adoptive cellular therapy (ACT) us-
ng CAR-T cells, toxicity is the main obstacle to the widespread use of
ngineered T cells in cancer treatment. Although CRS and CRES (CAR T
ell-related encephalopathy syndrome) is the most common toxicities,
ther adverse effects such as ICANS (immune effector cell-associated
eurotoxicity syndrome) should be considered after CAR-T cell infusion
n clinical practice too [71] . 
Since the field of ACT using engineered T cells is still quite new,
herefore, the management of its toxicities requires a lot of research
nd time.Certainly, CAR-T cell toxicity management will change con-
iderably within the coming years as more data will be provided by the
tudies. By now, results of studies on the pathophysiology of CRS and
eurotoxicity have shown that the early and peak levels of certain cy-
okines, patient disease burden, peak blood CAR T-cell levels, CAR T-cell
ose, endothelial activation, and CAR design may play a role in CAR-
 cell toxicities [72] . According to this data, different approaches are
eveloped to overcome the toxicities of CAR-T cell therapy. 
Systems using suicide genes, such as iCasp9 and tEGFR that are fol-
owed by the administration of the antibody or small dimerizer molecule
gents to induce apoptosis in the transduced cells with the transgene,
re under investigation for the toxicity management. Nevertheless, these
ystems affect the anti-malignancy activity of the therapy by the irre-
ersible elimination of therapeutic CAR-T cells so that these systems may
e more effective in case of life-threatening toxicity not controlled with
mmunosuppression or in the setting of ongoing long-term toxicities af-
er malignancy remission. Another approach to overcome the toxicities







































































































s by using endogenous switches such as synNotch and iCAR to intra-
ellularly regulate CAR-T cells in a self-switch manner. In this method,
he time and intensity of CAR-T cell activity cannot be controlled. Bis-
ecific T cell engager and on-switch CAR system using exogenous small
olecules are under evaluation too [36 , 72] . 
Altogether, toxicity management of the CAR-T cell therapy requires
ore research to eliminate shortcomings of the present approaches or
ntroduce new methods. It is hoped that the development of the later
eneration CARs will increase the safety of cancer treatment using CAR-
 cells and overcomes its present weaknesses. 
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